Thailand's removal of official who supported compulsory licensing 'important' step to 'protecting patients' health,' editorial says

The Thai government's removal last week of Vichai Chokevivat -- "one of the most vocal opponents" of patent protections for drug companies -- from Governmental Pharmaceutical Organization's board is a "small" but "important" step in "restoring Thailand's international reputation and protecting patients' health," a Wall Street Journal Asia editorial says.

Vichai "strongly supported" Thailand's efforts to issue compulsory licensing for certain medications, including antiretroviral drugs, according to the editorial. According to the Journal, Vichai's argument that the government "was acting according to domestic and international law" is "debatable, at best," in part because Thailand does not "have an HIV/AIDS epidemic like sub-Saharan Africa."

The editorial says that Thai Health Minister Chaiya Sasomsup, who took office in February, "deserves kudos" for pledging to review the country's patent polices and for removing "harmful public voices" such as Vichai's. Chaiya "understands" that pharmaceutical companies will not "devote significant resources to researching Thai-specific diseases" if the companies are not "compensated for their innovations," according to the Journal. It is "[f]ar better" for Thailand to "encourage world-class, private drug companies to invest" in the country and "work with the government on better drug pricing schemes and delivery programs," the editorial says, concluding that Chaiya's "quiet war for property rights" is "in the best interest of Thai patients" (Wall Street Journal Asia, 5/29).


Kaisernetwork.orgThis article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2007 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Two studies on gastrointestinal stroma tumors describe advances that may lead to new treatments